MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy

E-ISSN： 2212-3873|9|4|344-352

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.9, Iss.4, 2009-01, pp. : 344-352

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy

Current Pharmaceutical Design, Vol. 24, Iss. 1, 2018-03 ,pp. : 78-83

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Cancer / Anti-Tumor

Current Bioactive Compounds, Vol. 1, Iss. 1, 2005-04 ,pp. : 1-24

Bentham Science Publishers

Access to resources Recommend Favorite

Lentiviral Vectors for Anti-Tumor Immunotherapy

Current Gene Therapy, Vol. 8, Iss. 6, 2008-12 ,pp. : 438-448

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Tumor Monoclonal Antibodies in Conjunction with &bgr;-Glucans: A Novel Anti- Cancer Immunotherapy

Current Medicinal Chemistry, Vol. 19, Iss. 25, 2012-09 ,pp. : 4298-4305

Bentham Science Publishers

Access to resources Recommend Favorite

Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research

By Bhargava Arpit Mishra Dinesh Banerjee Smita Mishra Pradyumna Kumar

Journal of Drug Targeting, Vol. 21, Iss. 2, 2013-02 ,pp. : 126-136

Informa Healthcare

Access to resources Recommend Favorite